PT892636E - Solucoesoftalmicas tornadas viscosas com polissacarido de semente de tamarindo - Google Patents

Solucoesoftalmicas tornadas viscosas com polissacarido de semente de tamarindo Download PDF

Info

Publication number
PT892636E
PT892636E PT97902574T PT97902574T PT892636E PT 892636 E PT892636 E PT 892636E PT 97902574 T PT97902574 T PT 97902574T PT 97902574 T PT97902574 T PT 97902574T PT 892636 E PT892636 E PT 892636E
Authority
PT
Portugal
Prior art keywords
tamarind gum
weight
ophthalmic
polysaccharide fraction
tamarind
Prior art date
Application number
PT97902574T
Other languages
English (en)
Portuguese (pt)
Inventor
Pietro Bianchini
Marco Fabrizio Saettone
Boris Giannaccini
Susi Burgalassi
Enrico Boldrini
Giulio Luciani
Original Assignee
Farmigea Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmigea Spa filed Critical Farmigea Spa
Publication of PT892636E publication Critical patent/PT892636E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97902574T 1996-02-05 1997-02-04 Solucoesoftalmicas tornadas viscosas com polissacarido de semente de tamarindo PT892636E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000075A IT1283911B1 (it) 1996-02-05 1996-02-05 Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo

Publications (1)

Publication Number Publication Date
PT892636E true PT892636E (pt) 2002-02-28

Family

ID=11403863

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97902574T PT892636E (pt) 1996-02-05 1997-02-04 Solucoesoftalmicas tornadas viscosas com polissacarido de semente de tamarindo

Country Status (14)

Country Link
US (1) US6056950A (ko)
EP (1) EP0892636B1 (ko)
JP (1) JP3872515B2 (ko)
KR (1) KR100430260B1 (ko)
AT (1) ATE204745T1 (ko)
AU (1) AU1617897A (ko)
CA (1) CA2245617C (ko)
DE (1) DE69706410T2 (ko)
DK (1) DK0892636T3 (ko)
EA (1) EA001067B1 (ko)
ES (1) ES2164327T3 (ko)
IT (1) IT1283911B1 (ko)
PT (1) PT892636E (ko)
WO (1) WO1997028787A1 (ko)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
CN100408100C (zh) 1997-07-29 2008-08-06 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
EP1156809B1 (en) 1999-03-01 2005-12-07 Vista Scientific LLC Mucin containing ophthalmic preparations
WO2002049610A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
AU2002232437A1 (en) 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic lubricating solution adapted for use in lasik surgery
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
ES2314049T3 (es) * 2001-02-15 2009-03-16 Access Pharmaceuticals, Inc. Formulaciones liquidas para la prevencion y el tratamiento de enfermedades y trastornos de la mucosa.
US6465506B2 (en) * 2001-02-22 2002-10-15 Ophthalmic Research Associates, Inc. Instillation techniques for ophthalmic agents to enhance treatment effect
KR20040019299A (ko) 2001-06-29 2004-03-05 바이오비트럼 에이비 대량 오토클레이빙 방법
CN1319597C (zh) * 2001-08-10 2007-06-06 东丽株式会社 含多糖组合物及其用途
US20040220089A1 (en) * 2001-10-03 2004-11-04 Ellis Edward J. Ophthalmic preparation containing glycoprotein
US20040214754A1 (en) * 2001-10-03 2004-10-28 Ellis Edward J. Ophthalmic preparation containing glycomacropeptide
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2316459B1 (en) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ, インコーポレイテッド 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20070077278A1 (en) * 2003-11-10 2007-04-05 Yukiko Sugihara Polysaccharide-containing composition and tear film stabilizing ophthalmic solution
US20050210732A1 (en) * 2004-03-26 2005-09-29 Guerin John W Crank bait tail
JP4395016B2 (ja) * 2004-06-29 2010-01-06 日清オイリオグループ株式会社 ゲル状吸水用組成物
ATE429209T1 (de) * 2005-02-09 2009-05-15 Safilens S R L Kontaktlinse, verfahren zu ihrer herstellung und packung zur aufbewahrung und pflege einer kontaktlinse
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050388A1 (it) * 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5134778B2 (ja) * 2006-03-10 2013-01-30 日清オイリオグループ株式会社 ゲル組成物及び該ゲル組成物を使用したパック化粧料
EP2420505A1 (en) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
ITRM20070510A1 (it) 2007-10-02 2009-04-03 Rmfa Trading S A Composizioni oftalmiche a base di polisaccaride del seme di tamarindo e acido ialuronico.
GB0719969D0 (en) 2007-10-12 2007-11-21 Cambridge Entpr Ltd Substance monitoring and control in human or animal bodies
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP2382210B1 (en) 2008-12-30 2017-03-01 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
PE20150621A1 (es) 2009-01-23 2015-05-07 Rigel Pharmaceuticals Inc Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
AU2010281404A1 (en) 2009-07-28 2012-02-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
IT1396607B1 (it) * 2009-11-16 2012-12-14 Hmfra Hungary Ltd Liability Company Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso.
IT1397132B1 (it) 2009-12-01 2013-01-04 Alfa Wassermann Spa Composizioni comprendenti antiinfiammatori non steroidei.
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
EP2563771B1 (en) 2010-04-24 2015-11-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2800382C (en) 2010-05-24 2019-09-17 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of microbial infections
CN103025387B (zh) * 2010-05-24 2016-06-01 因德纳有限公司 用于治疗炎性疾病的罗望子种子多糖
JP5620168B2 (ja) * 2010-06-30 2014-11-05 Dsp五協フード&ケミカル株式会社 キシログルカン−カチオン複合体及びそれを含有する安定化組成物
HUE028534T2 (en) * 2010-07-12 2016-12-28 Zambon Spa Tamarind polysaccharide derived from wood seeds for use in the treatment of dry cough
ES2880622T3 (es) 2010-07-28 2021-11-25 Rigel Pharmaceuticals Inc Composiciones y procedimientos para la inhibición de la ruta de JAK
ES2600928T3 (es) 2010-08-27 2017-02-13 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden derivados de alcohol perilílico
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
BR112013011830B1 (pt) 2010-11-13 2022-03-15 Innocrin Pharmaceuticals, Inc Composto inibidor de metaloenzima, composição que compreende o dito composto, bem como uso do mesmo para tratar uma doença ou transtorno relacionado à metaloenzima
US9169182B2 (en) 2011-02-25 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit FtsZ protein
ITMI20110583A1 (it) 2011-04-08 2012-10-09 Hmfra Hungary Ltd Liability Company Preparazioni oftalmiche a base di pacap (pituitary adenylate cyclase activating polypeptide) al fine di ripristinare la normale funzione visiva nel glaucoma in fase precoce
RU2463022C1 (ru) * 2011-04-19 2012-10-10 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения больных с синдромом "сухого глаза"
EP2701722A4 (en) 2011-04-28 2014-12-31 Univ Southern California CANCEROUS MARKERS OF HUMAN SUPPRESSIVE MYELOID CELLS
CN105884743B (zh) 2011-06-19 2019-08-06 威尔金制药(Nc)有限公司 金属酶抑制剂化合物
KR20140040235A (ko) 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
AU2012273004B2 (en) 2011-06-23 2017-04-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
RS54138B1 (en) 2011-08-12 2015-12-31 Zambon S.P.A. USE OF TAMARIND WOOD POLYMAHARID POLYMERS IN PROTECTION AGAINST DAMAGE RELATED TO TOBACCO
RU2598721C2 (ru) * 2011-09-07 2016-09-27 Сэндзю Фармасьютикал Ко., Лтд. Способ подавления снижения вязкости жидкого водного агента
WO2013046059A2 (en) * 2011-09-27 2013-04-04 Sykora Robert C Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
SI2788343T1 (sl) 2011-12-11 2019-09-30 Viamet Pharmaceuticals (NC), Inc. Spojine inhibitorja metaloencimov
KR102061137B1 (ko) 2012-01-20 2019-12-31 마이코비아 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
WO2013142038A2 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP3016634A2 (en) * 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
EP2883931A1 (en) * 2013-12-12 2015-06-17 Omya International AG Improved gel stability
EP3131568B1 (en) 2014-04-15 2018-06-06 Novintethical Pharma SA Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
EP3872069A1 (en) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
ES2705692T3 (es) 2015-06-11 2019-03-26 Novintethical Pharma Sa Composiciones nasales tópicas que contienen xiloglucanos para usar como descongestionantes
CN108135956B (zh) * 2015-07-13 2021-06-08 东北泰克诺亚奇股份有限公司 视神经保护用组合物
WO2017023941A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
WO2017025983A1 (en) 2015-08-07 2017-02-16 Council Of Scientific & Industrial Research A lubricant formulation of carbamoylethyl katira and a process for preparation thereof
EA038421B1 (ru) 2015-12-30 2021-08-26 ВиПиЭс-3, ИНК. Соединения, ингибирующие металлоферменты
EP3475263B1 (en) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
EP4212523A1 (en) 2016-10-26 2023-07-19 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
ES2939232T3 (es) 2016-10-26 2023-04-20 Rigel Pharmaceuticals Inc Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación
WO2018102412A1 (en) 2016-11-30 2018-06-07 Neonc Technologies, Inc. A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2019006126A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM
US11129862B2 (en) * 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
US20210228498A1 (en) 2018-02-08 2021-07-29 Neonc Technologies, Inc. Methods of permeabilizing the blood brain barrier
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
MD3788044T2 (ro) 2018-05-03 2023-12-31 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
JP2022543843A (ja) 2019-08-08 2022-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
EP4013420B1 (en) 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
MX2022002292A (es) 2019-08-30 2022-06-02 Rigel Pharmaceuticals Inc Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones.
EP4025568A1 (en) 2019-09-06 2022-07-13 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
US11564930B2 (en) 2019-09-06 2023-01-31 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
CA3156594A1 (en) 2019-11-07 2021-05-14 Yan Chen Heterocyclic rip1 inhibitory compounds
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為irak抑制劑的嘧啶—2—基—吡唑化合物
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
JPH0748278A (ja) * 1992-06-10 1995-02-21 Taiho Yakuhin Kogyo Kk 鼻腔用粉末製剤

Also Published As

Publication number Publication date
JP2000504685A (ja) 2000-04-18
EP0892636B1 (en) 2001-08-29
JP3872515B2 (ja) 2007-01-24
DE69706410D1 (de) 2001-10-04
CA2245617A1 (en) 1997-08-14
DK0892636T3 (da) 2001-12-17
AU1617897A (en) 1997-08-28
EA199800689A1 (ru) 1999-02-25
IT1283911B1 (it) 1998-05-07
EA001067B1 (ru) 2000-10-30
DE69706410T2 (de) 2002-06-06
US6056950A (en) 2000-05-02
ITRM960075A1 (it) 1997-08-05
ATE204745T1 (de) 2001-09-15
KR100430260B1 (ko) 2004-07-30
CA2245617C (en) 2005-07-12
ES2164327T3 (es) 2002-02-16
EP0892636A1 (en) 1999-01-27
KR19990082244A (ko) 1999-11-25
WO1997028787A1 (en) 1997-08-14
ITRM960075A0 (it) 1996-02-05

Similar Documents

Publication Publication Date Title
PT892636E (pt) Solucoesoftalmicas tornadas viscosas com polissacarido de semente de tamarindo
Ranch et al. Optimization of a novel in situ gel for sustained ocular drug delivery using Box-Behnken design: In vitro, ex vivo, in vivo and human studies
EP2197456B1 (en) Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid
Rajoria et al. In-situ gelling system: a novel approach for ocular drug delivery
KR940000229B1 (ko) 생리학적 액체와 접촉하여 겔화되는 약제학적 조성물의 제조방법
Majeed et al. Ocular in situ gel: An overview
JP3795105B2 (ja) 人工涙として使用するための眼用製剤
Rathore In situ gelling ophthalmic drug delivery system: an overview
AU2016344349B2 (en) Pharmaceutical formulations that form gel in situ
Noreen et al. Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery
RU2663449C2 (ru) Глазные композиции, содержащие мукоадгезивные полисахариды, способные стимулировать восстановление эпителия роговицы
JP2018531292A6 (ja) インサイチュでゲルを形成する医薬製剤
Bernatchez et al. Use of hyaluronic acid in ocular therapy
JP2011513393A (ja) 眼用組成物
KR102268002B1 (ko) 효과 지속성 점안제 조성물
Arshinoff et al. HsS versus a balanced salt solution as a corneal wetting agent during routine cataract extraction and lens implantation
CA2346631C (en) Antibacterial aqueous ophthalmic formulations containing ofloxacin and use of chitosan for solubilizing ofloxacin suspended in an aqueous media
de Castro et al. Tamarind seed polysaccharide (TSP) uses in ophthalmic drug delivery
DK3229780T3 (en) Ophthalmic composition for use in the treatment of dry eye syndrome
EP3682867B1 (en) Lutein-containing ophthalmic composition
Sharma et al. Ocular Bioadhesive Drug Delivery Systems and Their Applications
Karan et al. In-Situ Ocular Gel-A Novel Approach Towards Ocular Drug Delivery
Gupta et al. Ophthalmic drug delivery systems with emphasis on in-situ hydrogels
Ali et al. An insight of natural polymers in ocular drug delivery systems
WO1994023752A1 (en) Drug delivery system